Anti-Inflammatory Drugs · Module 2 of 4

NSAID Toxicity, Drug Interactions, and Special Populations

GI ulcerogenesis, cardiovascular risk, renal toxicity, and high-risk prescribing

NSAID gastropathy is a systemic pharmacological effect, not a local irritant effect — enteric-coated and parenteral NSAIDs cause the same rate of gastric mucosal injury as plain oral tablets because prostaglandin suppression in the mucosa is driven by drug absorbed into the bloodstream; only COX-2 selectivity (celecoxib) or prostaglandin replacement (misoprostol) or acid suppression (PPI, ~75% relative risk reduction) address the underlying mechanism; a dangerous feature is that NSAIDs suppress the prostaglandin-mediated pain sensitization that makes ulcers symptomatic — serious GI bleeding can occur without warning.
Cardiovascular risk tracks with COX-2 selectivity — selective COX-2 inhibitors suppress endothelial PGI2 while leaving platelet TXA2 intact, creating a prothrombotic state (rofecoxib and valdecoxib withdrawn); high-dose diclofenac and high-dose ibuprofen carry equivalent cardiovascular risk to COX-2 selective agents; naproxen has the most favorable cardiovascular profile and is preferred when a patient with CV risk factors cannot avoid an NSAID; all NSAIDs carry a class-wide black box cardiovascular warning.
Renal toxicity is COX-isoform-independent because both COX-1 and COX-2 contribute to renal prostaglandin synthesis — in euvolemic healthy patients renal risk is minimal; in heart failure, cirrhosis with ascites, CKD, and volume depletion the kidney becomes prostaglandin-dependent for afferent arteriolar dilation, and NSAID-mediated suppression can precipitate acute kidney injury rapidly; NSAIDs also cause sodium/water retention, hyperkalemia, and blunt antihypertensive efficacy.
The triple whammy (NSAID + ACE inhibitor/ARB + diuretic) is one of the highest-risk drug combinations in ambulatory medicine — the NSAID removes prostaglandin-dependent afferent arteriolar dilation; the ACE inhibitor/ARB blocks angiotensin II-dependent efferent arteriolar constriction; the diuretic reduces circulating volume; together they produce a severe GFR decline; avoid this combination or monitor creatinine and electrolytes within 1–2 weeks if unavoidable.
Third-trimester NSAIDs are strongly contraindicated — PGE2 maintains fetal ductus arteriosus patency through receptor-mediated vasodilation; COX inhibition from week 28 onward can cause premature ductal closure, leading to fetal right ventricular pressure overload; NSAIDs from 20 weeks onward can cause oligohydramnios from fetal renal dysfunction; acetaminophen is the preferred analgesic at all trimesters; low-dose aspirin (81 mg/day) for preeclampsia prevention is a specific evidence-based exception under obstetric supervision.

Abbreviations: COX = cyclooxygenase · PGE2 = prostaglandin E2 · PGI2 = prostacyclin · TXA2 = thromboxane A2 · AERD = aspirin-exacerbated respiratory disease · PPI = proton pump inhibitor · eGFR = estimated glomerular filtration rate · ACE = angiotensin-converting enzyme · ARB = angiotensin receptor blocker · SSRI = selective serotonin reuptake inhibitor · CKD = chronic kidney disease · GFR = glomerular filtration rate · CV = cardiovascular

NSAID Toxicity — Three Organ Systems

GI Toxicity — COX-1 Dependent

Systemic Mechanism, Not Topical

COX-1 in gastric mucosa → PGE2/PGI2 → mucus, bicarbonate, blood flow, acid inhibition
NSAIDs suppress all four mucosal defenses simultaneously
Enteric coating and parenteral routes do NOT reduce gastric injury — systemic mechanism
Ulcers often painless — NSAIDs suppress the prostaglandin sensitization that makes ulcers hurt
Prevention: celecoxib (COX-2 selective); nonselective NSAID + PPI (~75% RR reduction); highest risk: celecoxib + PPI
Misoprostol (PGE1 analog): replaces mucosal prostaglandin; limited by diarrhea

CV Risk — COX-2 Selectivity Driven

PGI2/TXA2 Imbalance

Endothelium: COX-2 → PGI2 (antiplatelet, vasodilatory)
Platelets: COX-1 → TXA2 (pro-aggregatory, vasoconstrictive)
Selective COX-2 inhibitors: suppress PGI2, leave TXA2 intact → prothrombotic → ↑ MI and stroke
High-dose diclofenac and ibuprofen = comparable CV risk to COX-2 selective agents
Naproxen: most favorable CV profile — sustained COX-1 inhibition → partial antiplatelet effect
All NSAIDs carry class-wide black box CV warning; use lowest dose, shortest duration

Renal Toxicity — COX-Isoform Independent

Prostaglandin-Dependent Perfusion

Both COX-1 and COX-2 contribute to renal prostaglandin synthesis — selectivity is irrelevant
Euvolemic healthy patients: minimal GFR reduction
Heart failure, cirrhosis, CKD, volume depletion: kidney depends on PG-mediated afferent arteriolar dilation — NSAID removes this → rapid AKI
Sodium/water retention, hyperkalemia, blunted antihypertensive efficacy
Avoid in eGFR <30 mL/min/1.73m²; contraindicated in decompensated heart failure and cirrhosis

GI Risk Stratification and Prevention Strategy

GI Risk Level	Risk Factors Present	Recommended Strategy
Low	No risk factors; age <65; no anticoagulant, corticosteroid, or prior ulcer	Nonselective NSAID alone at lowest effective dose
Moderate	1–2 risk factors: age ≥65, concurrent anticoagulant or corticosteroid, high NSAID dose, or H. pylori	Celecoxib alone — OR — nonselective NSAID + PPI. Test and treat H. pylori
High	Prior peptic ulcer or GI bleed; multiple risk factors; dual NSAID (incl. + low-dose aspirin)	Celecoxib + PPI — highest gastroprotection; avoid nonselective NSAID if possible
Absolute avoidance	Active peptic ulcer; confirmed AERD on non-selective NSAID; eGFR <30; decompensated HF; Child-Pugh B/C cirrhosis; pregnancy ≥28 weeks	No NSAID; use acetaminophen. AERD: use celecoxib if NSAID required

Drug Interactions and Special Population Rules

High-Yield Drug Interactions

Five Mechanisms, Five Consequences

+ Anticoagulants (warfarin/DOACs): 2–4× GI bleed risk → use PPI, minimize duration
Triple whammy (+ ACE-I/ARB + diuretic): remove PG-afferent dilation + block efferent constriction + ↓ volume → severe AKI; avoid; if unavoidable check creatinine/K⁺ in 1–2 weeks
+ Lithium: reduce renal lithium clearance → levels ↑ 10–60%; check within 5–7 days
+ High-dose methotrexate: impair tubular secretion → prolonged MTX exposure → myelosuppression; do not use within 24 h of infusion
+ SSRIs: SSRIs deplete platelet serotonin + NSAIDs block TXA2 → additive platelet dysfunction → ↑ GI bleeding → use PPI
+ Antihypertensives: 3–5 mmHg average BP rise (Na retention + vasoconstriction); calcium channel blockers relatively spared

Special Populations

Pregnancy, Elderly, CKD, Cirrhosis

Pregnancy ≥28 weeks: strongly contraindicated — PGE2 maintains ductus arteriosus patency; COX inhibition → premature closure → right ventricular overload
Pregnancy ≥20 weeks: oligohydramnios risk (fetal renal PG suppression) — ultrasound monitoring if NSAID continued
Low-dose aspirin 81 mg/day in pregnancy: approved exception for preeclampsia prevention under obstetric supervision
Elderly ≥65: avoid oral nonselective NSAIDs (Beers Criteria); reduced renal reserve (creatinine underestimates GFR), reduced mucosal regeneration, polypharmacy
Topical diclofenac gel: effective local analgesia for hand/knee OA with minimal systemic absorption — preferred in elderly
CKD (eGFR <30): avoid; CKD G3 (eGFR 30–60): short-term lowest dose with close monitoring; cirrhosis Child-Pugh B/C: contraindicated

AERD — Pathophysiology and Drug Selection

AERD (aspirin-exacerbated respiratory disease; Samter triad) affects ~10–20% of adults with asthma and ~30% with nasal polyps. Pathophysiology: constitutively elevated leukotriene production from the LOX pathway + deficient PGE2-mediated suppression of mast cell and eosinophil activation. When any COX-1 inhibiting NSAID is taken, the remaining PGE2 restraint is removed and more arachidonic acid diverts from the blocked COX pathway into the already overactive LOX pathway → surge of cysteinyl leukotrienes → bronchoconstriction, rhinorrhea, urticaria within 30–180 minutes.

Perioperative NSAID management: non-aspirin NSAIDs inhibit COX-1 reversibly — platelet function recovers as drug clears. Hold short-acting agents (ibuprofen, diclofenac, ketorolac) 24 hours before significant bleeding-risk procedures. Hold naproxen 3–5 days (t½ 12–17 h; 5 half-lives). Aspirin's inhibition is irreversible — platelet function not fully restored until new platelets repopulate over 7–10 days; in secondary cardiovascular prevention, weigh procedural bleeding risk against thrombotic risk of stopping aspirin before deciding.

Suggested References

Author / Source	Title	Publication
Katzung BG, ed.	Basic and Clinical Pharmacology, 15th ed. — Chapter 40: Estrogens, Progestins, and the Female Reproductive Tract	McGraw-Hill; 2021
Brunton L, Knollmann B, Hilal-Dandan R, eds.	Goodman & Gilman's The Pharmacological Basis of Therapeutics, 14th ed. — Chapter 44: Estrogens and Progestins	McGraw-Hill; 2023
Lanas A, Chan FKL.	Peptic ulcer disease	Lancet. 2017;390(10094):613–624
Sostres C, Gargallo CJ, Lanas A.	Nonsteroidal anti-inflammatory drugs and upper and lower gastrointestinal mucosal damage	Arthritis Res Ther. 2013;15(Suppl 3):S3
Lanza FL, Chan FK, Quigley EM; American College of Gastroenterology.	Guidelines for prevention of NSAID-related ulcer complications	Am J Gastroenterol. 2009;104(3):728–738
FitzGerald GA.	Coxibs and cardiovascular disease	N Engl J Med. 2004;351(17):1709–1711
Bhala N, Emberson J, Merhi A, et al; CNT Collaboration.	Vascular and upper gastrointestinal effects of non-steroidal anti-inflammatory drugs: meta-analyses of individual participant data from randomised trials	Lancet. 2013;382(9894):769–779
American Geriatrics Society.	2023 updated AGS Beers Criteria for potentially inappropriate medication use in older adults	J Am Geriatr Soc. 2023;71(7):2052–2081
Whelton A.	Nephrotoxicity of nonsteroidal anti-inflammatory drugs: physiologic foundations and clinical implications	Am J Med. 1999;106(5B):13S–24S
Lapi F, Azoulay L, Yin H, Nessim SJ, Suissa S.	Concurrent use of diuretics, angiotensin converting enzyme inhibitors, and angiotensin receptor blockers with non-steroidal anti-inflammatory drugs and risk of acute kidney injury	BMJ. 2013;346:e8525
Boelsterli UA.	Diclofenac-induced liver injury: a paradigm of idiosyncratic drug toxicity	Toxicol Appl Pharmacol. 2003;192(3):307–322
Patrono C, Baigent C.	Role of aspirin in primary prevention of cardiovascular disease	Nat Rev Cardiol. 2019;16(11):675–686
Stevenson DD, Sanchez-Borges M, Szczeklik A.	Classification of allergic and pseudoallergic reactions to drugs that inhibit cyclooxygenase enzymes	Ann Allergy Asthma Immunol. 2001;87(3):177–180
Rainsford KD.	Anti-inflammatory drugs in the 21st century	Subcell Biochem. 2007;42:3–27
Bloor M, Paech M.	Nonsteroidal anti-inflammatory drugs during pregnancy and the initiation of lactation	Anesth Analg. 2013;116(5):1063–1075